Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.67 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17274465 | 0.98 | MIF (0.65) | MIFCNR2SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4594809 | 0.95 | MIF (0.69) | MIFCNR2SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL1526826 | 0.88 | MIF (0.73) | MIFSIGMAR1KDM4EALDH1A1HTR2A | |
| SCHEMBL380831 | 0.83 | MIF (0.45) | MIFCNR2SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL4304143 | 0.83 | MIF (0.45) | MIFCNR2SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL11240238 | 0.82 | MIF (0.44) | MIFCNR2ALDH1A1HTR2AKCNH2 | |
| SCHEMBL8101546 | 0.81 | MIF (0.54) | MIFNAAA | |
| SCHEMBL3915370 | 0.80 | MIF (1.00) | MIFALDH1A1HTR2ANOS3NOS2 | |
| SCHEMBL8101646 | 0.80 | MIF (0.57) | MIFALDH1A1NAAA | |
| SCHEMBL28806778 | 0.78 | MIF (0.46) | MIFCNR2SIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4424327-A1 | METHOD OR AGENT WITH HDAC REGULATOR, FOR TREATMENT OF DIABETES AND COMPLICATIONS | Biozipcode, Inc. (JP) | 2024-09-04 | — | — | EP | claimed |
| CN-118475370-A | Methods or agents for treating diabetes and complications based on HDAC modulators | 比奥兹普科德公司 | 2024-08-09 | — | — | CN | claimed |
| WO-2023074794-A1 | METHOD OR AGENT WITH HDAC REGULATOR, FOR TREATMENT OF DIABETES AND COMPLICATIONS | 国立大学法人滋賀医科大学 | 2023-05-04 | — | — | WO | claimed |
| WO-2010140902-A1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | HAMPTON MARK (NZ) | 2010-12-09 | — | — | WO | claimed |
| CN-100453076-C | Application of phenhexyl isothiocyanate in preparation of medicament for treating leukemia | XUDONG MA (CN) | 2009-01-21 | — | — | CN | claimed |
| CN-1961873-A | Application of phenhexyl isothiocyanate in preparation of medicament for treating leukemia | MA XUDONG (CN) | 2007-05-16 | — | — | CN | claimed |
| US-5231209-A | Phenylhexyl isothiocyanate | AMERICAN HEALTH FOUNDATION (US) | 1993-07-27 | — | — | US | claimed |
| US-12466789-B2 | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240279169-A9 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118475370-A | Methods or agents for treating diabetes and complications based on HDAC modulators | 比奥兹普科德公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230323299-A1 | POPULATION OF TREG CELLS FUNCTIONALLY COMMITTED TO EXERT A REGULATORY ACTIVITY AND THEIR USE FOR ADOPTIVE THERAPY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230321027-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUNDATION | 2023-10-12 | — | — | US | disclosed |
| EP-0871767-A4 | METHOD FOR AMPLIFYING SPECIFIC NUCLEIC ACID SEQUENCES | JOHNSON & JOHNSON RES PTY LTD (AU) | 1999-09-01 | — | — | EP | disclosed |
| EP-0871767-A1 | METHOD FOR AMPLIFYING SPECIFIC NUCLEIC ACID SEQUENCES | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 1998-10-21 | — | — | EP | disclosed |
| WO-1996032500-A1 | METHOD FOR AMPLIFYING SPECIFIC NUCLEIC ACID SEQUENCES | JOHNSON & JOHNSON RESEARCH PTY. LIMITED (AU) | 1996-10-17 | — | — | WO | disclosed |
| US-5231209-A | Phenylhexyl isothiocyanate | AMERICAN HEALTH FOUNDATION (US) | 1993-07-27 | — | — | US | disclosed |
| US-5231209-A | Phenylhexyl isothiocyanate | AMERICAN HEALTH FOUNDATION (US) | 1993-07-27 | — | — | US | disclosed |
| US-5114969-A | Method of inhibiting lung tumors, arylalkyl isothiocyanates, and method of synthesizing same | AMERICAN HEALTH FOUNDATION (US) | 1992-05-19 | — | — | US | disclosed |
| US-5114969-A | Method of inhibiting lung tumors, arylalkyl isothiocyanates, and method of synthesizing same | AMERICAN HEALTH FOUNDATION (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466789-B2 | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use | F12, MSR1, TST | MIF 1902/4885CNR2 2268/4885SIGMAR1 297/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | MIF 2371/4885CNR2 3341/4885SIGMAR1 1720/4885 |
| US-20240279169-A9 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | F12, MSR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MIF 2036/4885CNR2 1287/4885SIGMAR1 91/4885 |
| US-20230321027-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, CFTR, SGMS1 | MIF 2781/4885CNR2 2184/4885SIGMAR1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.